Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Other financing activities (2016 - 2025)

Integra Lifesciences Holdings' Other financing activities history spans 14 years, with the latest figure at $134000.0 for Q4 2025.

  • For Q4 2025, Other financing activities changed N/A year-over-year to $134000.0; the TTM value through Dec 2025 reached $209000.0, changed N/A, while the annual FY2025 figure was $4.1 million, N/A changed from the prior year.
  • Other financing activities for Q4 2025 was $134000.0 at Integra Lifesciences Holdings, up from $75000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $7.6 million in Q1 2023 and bottomed at $75000.0 in Q3 2025.
  • The 3-year median for Other financing activities is $249000.0 (2021), against an average of $1.7 million.